Tripride 2 Forte Tablets contain Glimepiride 2 mg, Pioglitazone 15 mg, and Metformin Hydrochloride 1000 mg in sustained-release form. This triple-drug combination is designed to provide comprehensive glycaemic control through complementary mechanisms of action in adults with type 2 diabetes mellitus.

Tripride 2 Forte Tablets combine a sulfonylurea, a thiazolidinedione, and sustained-release Metformin to target multiple underlying defects of type 2 diabetes mellitus. Glimepiride stimulates insulin secretion from functioning pancreatic beta cells, Pioglitazone improves insulin sensitivity by activating PPAR-γ receptors, and Metformin decreases hepatic glucose production while enhancing peripheral glucose uptake and utilization. The sustained-release formulation of Metformin improves gastrointestinal tolerability and supports convenient once-daily dosing, making it suitable for patients requiring intensified glycaemic management.

Tripride 2 Forte Tablets are indicated for the treatment of Type 2 Diabetes Mellitus (T2DM) in adults whose glycaemic targets are not adequately achieved with diet, exercise, monotherapy, or dual oral antidiabetic therapy. The combination serves as an adjunct to lifestyle modifications to improve long-term glycaemic control.

Tripride 2 Forte Tablets exert their antihyperglycaemic effects through three complementary mechanisms. Glimepiride lowers blood glucose by stimulating insulin secretion from functioning pancreatic beta cells. Pioglitazone selectively activates peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in skeletal muscle, adipose tissue, and the liver through regulation of genes involved in glucose and lipid metabolism. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and increases peripheral glucose uptake and utilization, thereby improving insulin sensitivity and overall glycaemic control.

The recommended initial dosage is one tablet taken orally once daily, or as directed by the treating physician. Dosage should be individualized according to the patient's clinical response and glycaemic requirements.

Tripride 2 Forte Tablets are contraindicated in patients with renal impairment, metabolic acidosis including diabetic ketoacidosis, and in individuals with known hypersensitivity to Glimepiride, Pioglitazone, Metformin, or any component of the formulation.